CARM — Carisma Therapeutics Inc.

OTC · Health Care · Pharmaceuticals · CIK 1485003 ·
Last close
$0.00
Market Cap
$4.2K
52W High
$0.05
52W Low
$0.00
ADV30
33,148
Next earnings
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Sep 2025 45,250,000 43,814,000 44,717,000 6,554,000 2,777,000 7,421,000
Jun 2025 0 -5,778,000 -9,774,000 5,012,000 1,999,000 51,017,000
Mar 2025 3,729,000 -9,334,000 -9,266,000 15,953,000 7,740,000 52,615,000
Dec 2024 3,653,000 -17,855,000 -17,635,000 30,458,000 17,909,000 58,367,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-22,415,000
Investing CF
$687,000
Financing CF
$-2,376,000
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$0.31
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-279,902,000
Inventory
Receivables
$1,636,000
ST Investments
EBIT TTM
$10,847,000
Pretax Income TTM
$8,042,000
Interest Exp TTM
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$52,632,000
EBITDA
$14,177,000
Free Cash Flow
$13,047,375
Enterprise Value
$-2,010,815
Total Cash
$2,777,000
Total Debt
$762,000
Shares Out
41,845,078
Trailing EPS
$0.19
Book Value
$-0.02
ROE
ROA
33.0%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2024 19,632,000 -62,179,000 -60,477,000 30,458,000 58,367,000 -59,917,000
Dec 2023 14,919,000 -88,731,000 -86,879,000 89,554,000 63,022,000 -81,177,000
Dec 2022 9,834,000 -56,162,000 -61,226,000 72,153,000 214,823,000 -5,116,000
Dec 2021 0 -40,794,000 -40,784,000 35,449,000 9,425,000 -37,328,000

TTM Snapshot

Revenues TTM
$17,641,000
NetIncome TTM
$9,336,000
OpCashFlow TTM
$0
Assets (Latest)
$89,554,000
Forward EPS
$-0.91

Peers — same industry

TickerNameMarket CapLastDaily %
OCEA Ocean Biomedical, Inc. $46.5K $0.00
ADTX Aditxt, Inc. $129.8K $0.25
BDPT BIOADAPTIVES, INC. $132.1K $0.01
GCAN Greater Cannabis Company, Inc. $137.0K $0.14
RGBP Regen BioPharma Inc $153.6K $0.00

News headlines (Yahoo Finance, 1h cache)

CARMILA: Information Concerning the Total Number of Voting Rights and Share
2026-04-02 15:40 · Yahoo
Carmila Makes its 2025 Universal Registration Document Available
2026-04-01 14:02 · Yahoo
Liberate Bio gains licences for myeloid-specific CAR design patents
2026-03-06 11:11 · Yahoo
Liberate Bio Secures Myeloid-Optimized CAR Design Licenses to Advance In Vivo CAR-M Programs
2026-03-05 12:15 · Yahoo
Carisma Announces Delisting from Nasdaq and SEC Deregistration
2025-12-05 16:16 · Yahoo
BC-Most Active Stocks
2025-09-02 14:30 · Yahoo
Carisma Therapeutics, OrthoCellix enter definitive merger agreement
2025-06-24 17:07 · Yahoo
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
2025-06-23 11:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.